News

  1. Bridgewest Group Launches NovaCina, New Sterile Injectable CDMO 4/4/2023

    Global private investment firm, Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, launches new Contract Development and Manufacturing Organization (CDMO) focused on sterile injectable drug products. This follows the recent announcement on the acquisition of the Perth sterile injectable manufacturing plant from Pfizer.

  2. Harm Reduction Therapeutics And Catalent Sign Commercial Supply Agreement For Naloxone Nasal Spray To Reverse Opioid Overdoses 3/23/2023

    Harm Reduction Therapeutics, a 501(c)(3) non-profit pharmaceutical company whose mission is to prevent opioid overdose deaths by making low-cost naloxone available to everyone, and Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the signing of a commercial supply agreement.

  3. Scaling Up Capacity, Eitan Medical Opens New Manufacturing Facility Bolstered by Semi-Automated Production Lines 3/22/2023

    Eitan Medical, a global leader in advanced infusion therapy and drug delivery solutions across the care continuum, announced today the opening of its new manufacturing facility at the company’s headquarters. On-site manufacturing will support Eitan Medical’s production scale of its Pharmaceutical Solutions division.

  4. Societal CDMO Announces U.S. FDA Approval For Manufacturing Of Commercial Tablet At Gainesville, Georgia Site 3/20/2023

    Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the United States Food and Drug Administration (FDA) has approved the company as a manufacturer of a commercial tablet product.

  5. Stevanato Group Collaborates With Recipharm To Develop And Manufacture Pre-Fillable Syringes For Use In A New Soft Mist Inhaler For The Inhalation Of Sensitive Biological Products 3/16/2023

    The new strategic collaboration aims to provide innovative primary packaging to pharmaceutical and biopharmaceutical companies using Recipharm’s proprietary soft mist inhalers.

  6. Catalent And Bhami Research Laboratory Enter Into Licensing Agreement For Technology To Deliver High-Concentration Biologics Subcutaneously 3/16/2023

    Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, and Bhami Research Laboratory (BRL), today announced a licensing agreement that will provide Catalent with access to BRL’s formulation technology to help enable the subcutaneous delivery of high-concentration biologic therapies.

  7. PCI Pharma Services Expands Biologics Leadership With New Center Of Excellence Facility In The Midwest 3/15/2023

    PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced plans for a new 200,000-square-foot facility in Rockford, Illinois to enhance the organization’s capacity in injectable drug-device combination product assembly of both biologics and small molecules.

  8. Aenova Introduces New Sterile Strategy 3/10/2023

    Aenova Group, a leading international contract developer and manufacturer for the pharmaceutical and healthcare industries, presents its new sterile strategy. In the future, the focus in sterile production will be on expanding the sterile site in Latina (Italy). There, portfolio and capacities are being expanded, especially in the area of prefilled syringes (PFS) as well as intramammary syringes.

  9. Shuttle Pharmaceuticals Engages UI Pharmaceuticals For Formulation And Clinical Batch Manufacture Of Ropidoxuridine For Brain Tumor Clinical Trial 3/9/2023

    Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has signed an agreement with the University of Iowa (UI) Pharmaceuticals for formulation development and clinical batch manufacture of drug capsules of Ropidoxuridine.

  10. Marchesini Group Acquires Milan-Based Company M.A.R. S.p.A. 3/8/2023

    A new company is joining Marchesini Group. The latest arrival is M.A.R. S.p.A., a company from Lainate (Milan) specialised in the construction of machinery for packaging liquids and powders in glass and plastic bottles, syringes, carpules and other containers for the pharmaceutical industry. This operation further extends the array of technologies available to Marchesini Group for the packaging of products in the Pharma world.